Kymera Therapeutics

Kymera Therapeutics to Hold Investor Webcast on December 14 to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline

Dosing in KT-474 Phase 1 HS and AD patient cohort (Part C) complete KT-413 and KT-333 continuing in Phase 1 dose escalation KT-253 has completed IND enabling studies WATERTOWN, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical